Top-Rated StocksTop-Rated Krystal Biotech Stock Price, News & Analysis (NASDAQ:KRYS) $106.26 +2.03 (+1.95%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$103.69▼$106.3050-Day Range$96.00▼$122.1552-Week Range$69.81▼$132.68Volume188,759 shsAverage Volume364,454 shsMarket Capitalization$3.00 billionP/E RatioN/ADividend YieldN/APrice Target$146.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Krystal Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside37.9% Upside$146.56 Price TargetShort InterestBearish7.34% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment1.16Based on 3 Articles This WeekInsider TradingSelling Shares$3.18 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.89) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector152nd out of 957 stocksBiological Products, Except Diagnostic Industry21st out of 157 stocks 3.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $146.56, Krystal Biotech has a forecasted upside of 37.9% from its current price of $106.26.Amount of Analyst CoverageKrystal Biotech has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.34% of the outstanding shares of Krystal Biotech have been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 1.43%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 3.4 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Krystal Biotech this week, compared to 3 articles on an average week.Search Interest1 people have searched for KRYS on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,180,750.00 in company stock.Percentage Held by Insiders17.00% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.30% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow in the coming year, from ($3.89) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is -72.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is -72.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Krystal Biotech Stock (NASDAQ:KRYS)Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More KRYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Buy" from AnalystsNovember 27, 2023 | markets.businessinsider.comKrystal Biotech Says EMA Validated MAA For VYJUVEK For Dystrophic Epidermolysis BullosaDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 23, 2023 | morningstar.comKrystal Biotech Inc KRYSNovember 22, 2023 | finance.yahoo.comGoldman Sachs Says These 2 Healthcare Stocks Have up to 130% Upside PotentialNovember 20, 2023 | msn.comGoldman Sachs Initiates Coverage of Krystal Biotech (KRYS) with Buy RecommendationNovember 20, 2023 | msn.comGoldman starts Krystal Biotech at buy, cites Vyjuvek launchNovember 10, 2023 | finance.yahoo.comThis Stock Has Quadrupled in 5 Years. Can It Do It Again?December 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 9, 2023 | finance.yahoo.comKrystal Biotech to Present at the Stifel 2023 Healthcare ConferenceNovember 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cigna (CI), Krystal Biotech (KRYS) and MacroGenics (MGNX)November 7, 2023 | insidermonkey.comKrystal Biotech, Inc. (NASDAQ:KRYS) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comQ3 2023 Krystal Biotech Inc Earnings CallNovember 7, 2023 | finance.yahoo.comInvestors push Krystal Biotech (NASDAQ:KRYS) 11% lower this week, company's increasing losses might be to blameNovember 6, 2023 | forbes.comFor A Change There’s Optimism About A Gene Therapy’s Commercialization—Vyjuvek For Wound CareNovember 6, 2023 | msn.comKrystal Biotech GAAP EPS of $2.79 beats by $3.46, revenue of $8.6M beats by $2.31MNovember 6, 2023 | finance.yahoo.comKrystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business UpdateNovember 6, 2023 | finance.yahoo.comKrystal Biotech Inc (KRYS) Announces Q3 2023 Financial ResultsNovember 3, 2023 | msn.comKrystal Biotech Q3 2023 Earnings PreviewOctober 30, 2023 | finance.yahoo.comKrystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023October 25, 2023 | benzinga.comKrystal Biotech Stock (NASDAQ:KRYS), Analyst Ratings, Price Targets, PredictionsOctober 25, 2023 | msn.comCantor starts Krystal Biotech at overweight, cites Vyjuvek launchOctober 25, 2023 | nasdaq.comCantor Fitzgerald Initiates Coverage of Krystal Biotech (KRYS) with Overweight RecommendationOctober 21, 2023 | finance.yahoo.comKRYS Oct 2023 110.000 callSeptember 28, 2023 | finance.yahoo.comKrystal Biotech to Present at the Chardan 7th Annual Genetic Medicines ConferenceSeptember 25, 2023 | finance.yahoo.comKrystal Biotech, Inc. (NASDAQ:KRYS): Are Analysts Optimistic?September 22, 2023 | msn.comFDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408See More Headlines Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Stock Price Target$146.56 High Stock Price Target$160.00 Low Stock Price Target$118.00 Potential Upside/Downside+37.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,980,000.00 Net MarginsN/A Pretax Margin-348.43% Return on Equity-21.45% Return on Assets-20.25% Debt Debt-to-Equity RatioN/A Current Ratio21.10 Quick Ratio20.91 Sales & Book Value Annual Sales$8.56 million Price / Sales350.30 Cash FlowN/A Price / Cash FlowN/A Book Value$26.80 per share Price / Book3.96Miscellaneous Outstanding Shares28,206,000Free Float23,411,000Market Cap$3.00 billion OptionableNot Optionable Beta0.84 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 58)M.S., Founder, Chairman, President & CEO Comp: $1.07MMs. Suma M. Krishnan (Age 58)Founder, COO, President of R&D and Director Comp: $789.92kMs. Kathryn A. Romano (Age 41)Executive VP & Chief Accounting Officer Comp: $528.87kMs. Meg DodgeVice President of Investor Relations & Corporate CommunicationsMr. John KarakkalVice President of North American Sales & MarketingMr. Josh SuskinDirector of Human Resources & OperationsDr. Hubert C. Chen M.D. (Age 54)Senior Vice President of Clinical Development Mr. Laurent GouxSenior VP & GM of EuropeMr. Ram KamineniSenior VP of CMC & Technical OperationsMr. David ChienSenior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsImmunityBioNASDAQ:IBRXGinkgo BioworksNYSE:DNADenali TherapeuticsNASDAQ:DNLIArcellxNASDAQ:ACLXBeam TherapeuticsNASDAQ:BEAMView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 365 shares on 11/24/2023Ownership: 0.048%Graham Capital Management L.P.Bought 2,849 shares on 11/22/2023Ownership: 0.010%Walleye Trading LLCSold 700 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCSold 2,100 shares on 11/21/2023Ownership: 0.000%TimesSquare Capital Management LLCBought 123,035 shares on 11/17/2023Ownership: 0.436%View All Insider TransactionsView All Institutional Transactions KRYS Stock Analysis - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price target for 2024? 9 equities research analysts have issued 12-month price targets for Krystal Biotech's shares. Their KRYS share price targets range from $118.00 to $160.00. On average, they expect the company's share price to reach $146.56 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2023? Krystal Biotech's stock was trading at $79.22 at the beginning of the year. Since then, KRYS stock has increased by 34.1% and is now trading at $106.26. View the best growth stocks for 2023 here. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings results on Monday, November, 6th. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $3.89. The firm earned $8.60 million during the quarter, compared to analysts' expectations of $6.29 million. The company's quarterly revenue was up 8500.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.17) EPS. What ETFs hold Krystal Biotech's stock? ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (9.32%), Redmile Group LLC (7.10%), Lord Abbett & CO. LLC (2.38%), Jennison Associates LLC (1.22%), Morgan Stanley (1.02%) and Skandinaviska Enskilda Banken AB publ (0.87%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:KRYS) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.